Wednesday 17th October 2012
|Text too small?|
Pacific Edge, the Dunedin-based DNA diagnostic test company, has completed work on its US-based laboratory on-schedule and on-budget and it now seeking regulatory approval for the building.
The purpose-built laboratory in Hershey, Pennsylvania, cost US$3.7 million and is expected to be fully operational by March 2013. It has to be approved by the Clinical Laboratory Improvement Amendment. The lab has a capacity to do 260,000 tests a year and will be operated by the company's wholly-owned subsidiary, Pacific Edge Diagnostics USA.
"The demanding timetable to launch this business is being met and the focus of the US team led by Jackie Walker is now on completion of the regulatory approvals, sales force deployment and marketing roll-out," chief executive, David Darling said in statement.
Pacific Edge shares rose 7.5 percent to 43 cents today. Last month, the stock was halted by NZX Market Supervision after they jumped to a then nine-year high, rising 13 percent to 34 cents. The stock has gained 100 percent this year.
No comments yet
Pacific Edge shares soar to new record on optimism about potential US growth
Pacific Edge at record-high after signing 2nd US health provider network
Masfen, long-term Pacific Edge backer, sells 10 mln shares near record high
Pacific Edge sees $100M revenue from US in five years
Pacific Edge bladder test validation bodes well for US sales
Pacific Edge signs Auckland distribution agreement for bladder test
Pacific Edge 1H loss narrows as company eyes US market for bladder test
Pacific Edge has pipeline of new products to follow new cancer-test patents
Pacific Edge secures patent for colorectal cancer detection technology